Camden Partners Holdings, LLC is pleased to announce its new growth equity investment in IPG, the nation’s leading device benefit management (DBM) company with a proven implant management platform and award-winning software-as-a-service (SaaS)-based solution for health plans.
Camden Partners Managing Member Christopher W. Kersey will serve on the company’s board of directors alongside CEO Jay Ethridge, one of the founding executives of Guidant Corporation which was ultimately purchased by Boston Scientific Corporation (NYSE: BSX) for more than $24 billion.
Current IPG investor Sequoia Capital is also participating in this Series C financing, and Sequoia’s Scott Carter and Michael Dixon will continue to serve on the company’s board of directors along with existing board member Dennis Antinori.
For more information on this financing, please visit http://www.pehub.com/2013/08/19/camden-partners-sequoia-capital-back-ipg
Named to the Inc. 5000 list of America’s fastest-growing companies for four consecutive years, Atlanta-based IPG is the leading nationwide provider of device benefit management (DBM) solutions. As a true benefit manager, IPG’s end-to-end DBM solutions serve as a strategic capability for health plans to manage cost and risk in a unique way that drives collaboration between the health plan, its healthcare providers, manufacturers and physicians to drive lower costs and high quality care for consumers.
IPG was recently selected for the CIO 100 award for its software-as-a-service (SaaS) platform, IPG Pathfinder 360, the cost and quality spotlight for implantable procedures. The new product leverages Big Data to understand the cost and practice variations around implant spend to manage risk and deliver actionable information to their stakeholders, while establishing collaborations among the parties that are delivering health care and rewarding effective cost and quality care for the consumer. For the complete CIO 100 announcement, please visit http://www.cio.com/cio100/2013/1